Viridian Therapeutics, Inc. (VRDN) Earnings Call Transcripts
Viridian Therapeutics, Inc.'s Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call, Viridian Therapeutics (VRDN) management expressed strong confidence ahead of their PDUFA date on June 30, 2026, for their lead product, Veli. They highlighted successful top-line results from pivotal studies REVEAL-1 and REVEAL-2, which support the drug's efficacy in treating thyroid eye disease (TED). Management maintained their guidance towards profitability, bolstered by a recent $300 million capital raise aimed at reducing debt and funding ongoing clinical programs. The company anticipates a significant market entry with Veli, targeting a $2 billion market currently dominated by TEPEZZA, while also advancing their FcRn and TSHR programs for future growth.
Reported metrics
| Metric | Value |
|---|---|
| PDUFA Date | June 30, 2026 (positive) |
| Capital Raised | $300 million (positive) |
| Sales Force Size | Under 100 (positive) |
| Market Coverage | 85% (positive) |
| Profitability Guidance | Maintained (positive) |
| BLA Submission Target | Q1 2027 (positive) |
Guidance from management
Management maintained guidance towards profitability, indicating they are more comfortable with their financial position following the recent capital raise. They also expect to advance their FcRn and TSHR programs in the near term.
What management said
And remember that this is a market that's primarily made up of women in their 40s and 50s. It's an autoimmune disease. These are people with very busy lives with families and jobs and just the active -- activities of daily life in that age group. And so the ability to bring, as Shan just referenced, a shorter treatment period of just 5 infusions, shorter infusion times, just on a logistics basis of the clinical profi...
Yes. The latter is the overwhelming response that we've gotten. It has been very consistent that there's a lot of excitement around the availability of a treatment option and a willingness to try that. I mean, for all the reasons that we talked about with the rapid onset, the diplopia data and the treatment regimen. Those are exciting prospects for the first time since -- in the last 6 years. So there's a lot of wi...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape, particularly the established presence of TEPEZZA and how Veli will differentiate itself in a market with existing treatment options. There were also questions about the adoption rate among prescribers familiar with TEPEZZA and their willingness to switch to a new treatment.
Main topics on the call
- PDUFA Date and Launch Readiness — Management confirmed a PDUFA date of June 30, 2026, stating, "We are all ready to go across the board" for the launch of Veli. This indicates strong operational preparedness and confidence in regulatory approval.
- Positive Clinical Trial Results — The results from REVEAL-1 and REVEAL-2 were described as "highly positive studies," with significant efficacy in proptosis response and diplopia, reinforcing the product's potential in the TED market.
- Capital Raise and Financial Position — Viridian raised $300 million to strengthen its balance sheet, with management stating, "We were guiding towards profitability before that deal, and we're obviously more comfortable...given additional capital." This posit...
- Market Dynamics and Competitive Positioning — Management believes that TEPEZZA's established market presence will benefit Veli, stating, "We think there's a lot of physician excitement about that." They aim to capture market share by offering a differentiated treatm...
Read the full Viridian Therapeutics, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 30 calls on record spanning March 11, 2020 to June 29, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 30 Viridian Therapeutics, Inc. earnings call transcripts on record, spanning March 11, 2020 to June 29, 2026. Based on this history, Viridian Therapeutics, Inc. reports quarterly. The most recent call on file is dated June 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VRDN
- Exchange
- NasdaqCM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 30
- First call
- March 11, 2020
- Most recent
- June 29, 2026
- Reporting cadence
- quarterly